303 related articles for article (PubMed ID: 15890579)
1. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
2. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
Beal K; Hudis C; Norton L; Wagman R; McCormick B
Breast J; 2005; 11(5):317-20. PubMed ID: 16174151
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
4. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Sartor CI; Peterson BL; Woolf S; Fitzgerald TJ; Laurie F; Turrisi AJ; Bogart J; Henderson IC; Norton L
J Clin Oncol; 2005 Jan; 23(1):30-40. PubMed ID: 15545661
[TBL] [Abstract][Full Text] [Related]
5. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
[TBL] [Abstract][Full Text] [Related]
7. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
[TBL] [Abstract][Full Text] [Related]
8. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy.
Minor GI; Yashar CM; Spanos WJ; Jose BO; Silverman CL; Carrascosa LA; Farmer M; Paris KJ
Breast J; 2006; 12(1):48-52. PubMed ID: 16409586
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
10. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
Koh ES; Sun A; Tran TH; Tsang R; Pintilie M; Hodgson DC; Wells W; Heaton R; Gospodarowicz MK
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):223-8. PubMed ID: 16904523
[TBL] [Abstract][Full Text] [Related]
11. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
Allen AM; Czerminska M; Jänne PA; Sugarbaker DJ; Bueno R; Harris JR; Court L; Baldini EH
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):640-5. PubMed ID: 16751058
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dose-response models and parameters predicting radiation induced pneumonitis using clinical data from breast cancer radiotherapy.
Tsougos I; Mavroidis P; Rajala J; Theodorou K; Järvenpää R; Pitkänen MA; Holli K; Ojala AT; Lind BK; Hyödynmaa S; Kappas C
Phys Med Biol; 2005 Aug; 50(15):3535-54. PubMed ID: 16030381
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
Fox AM; Dosoretz AP; Mauch PM; Chen YH; Fisher DC; LaCasce AS; Freedman AS; Silver B; Ng AK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):277-83. PubMed ID: 22019238
[TBL] [Abstract][Full Text] [Related]
14. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
[TBL] [Abstract][Full Text] [Related]
15. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.
Fay M; Tan A; Fisher R; Mac Manus M; Wirth A; Ball D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1355-63. PubMed ID: 15817337
[TBL] [Abstract][Full Text] [Related]
16. Risk of hypothyroidism in older breast cancer patients treated with radiation.
Smith GL; Smith BD; Giordano SH; Shih YC; Woodward WA; Strom EA; Perkins GH; Tereffe W; Yu TK; Buchholz TA
Cancer; 2008 Mar; 112(6):1371-9. PubMed ID: 18213620
[TBL] [Abstract][Full Text] [Related]
17. Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer.
Arnedos M; Sutherland S; Ashley S; Smith I
Breast Cancer Res Treat; 2008 Nov; 112(1):1-4. PubMed ID: 18060493
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients.
Rutqvist LE; Johansson H
Acta Oncol; 2006; 45(5):517-27. PubMed ID: 16864164
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
